Products are rare antisera blood typing reagents developed and manufactured by Quotient U.S. commercialization of these products will extend the range and method of reagents available in the market for antigen phenotyping Equivalent products are already approved and commercialized outside of the
Chris Lindop to Remain as Executive Vice President Reporting to Franz Walt CEO JERSEY, Channel Islands , Jan. 07, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the planned appointment of Peter Buhler as Chief Financial
JERSEY, Channel Islands , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced positive preliminary US field trial data on the Initial Serological Disease Screening (SDS) Microarray. “We are very encouraged by these results.
Successful Extended Immunohematology Verification and Validation data paving the way for field trials Positive customer feedback and three additional hypercare sites initiated Preliminary quarterly revenue higher than guided JERSEY, Channel Islands , Oct.
JERSEY, Channel Islands, April 21, 2016 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that its U.S. subsidiary, Quotient Biodiagnostics, Inc. ("Quotient Biodiagnostics"), has signed a national group purchasing agreement with Premier,
